ConnectSx

Revolutionizing the way surgical implants are tracked, managed, and used.

[ConnectSx @connectSX]

Medline’s launch of their Mpower control tower signals a shift in how healthcare systems handle inventory. By embedding demand forecasting and real-time tracking into one dashboard, they're pushing the entire industry away from reactive operations and toward predictive management.

For medical device manufacturers and sales operations, it’s a blueprint for where customer expectations are heading, and it highlights exactly where traditional field operations are falling short.

Hospital networks are investing heavily in this tech because they are tired of inventory blind spots. When a manufacturer or distributor cannot see field stock in real time, that operational burden gets pushed directly onto the provider.

If your commercial teams are still guessing at trunk stock levels, consignment volumes, or what is sitting in hospital closets, you are creating friction. Building trust today requires clean data connections and complete visibility, not just a reliable product.

We also have to look at the administrative burnout clinical teams are facing. Medline’s data showed that automating product substitution workflows cut traditional 5-to-7-day decision windows down dramatically during testing. A product’s true value now includes how easy it is to source, track, and bill.

Redundant paperwork, slow billing cycles, and surprise stockouts take time away from patient care. When you optimize your field logistics to eliminate these headaches, you become the preferred partner.

The goal moving forward has to be resolving supply chain disruptions before they ever reach the point of care. Right now, most sales reps and operations teams discover an inventory issue when a tray is already missing components or an item has expired on the shelf. Manufacturers need internal tracking systems that automatically flag low stock, high-turnover patterns, and looming expirations. Moving from a place of fixing errors to preventing shortages preemptively is how you protect revenue, enhance distribution, and secure customer relationsihps.

Read more from Medline here: https://t.co/LW4yfFctCA

[ConnectSx @connectSX]

Tariffs and geopolitical shifts are driving a significant push to reshore medical device manufacturing operations back to the United States.

The goals are clear: reduce lead times, mitigate international trade uncertainty, and regain control over critical supply chains.

But moving production closer to home does not automatically solve supply chain volatility.

Reshoring introduces a complex set of domestic hurdles. Manufacturers are quickly confronting a severe shortage of specialized, highly skilled labor required for advanced medical precision. Equipment requalification, new infrastructure demands, and the transfer of technical expertise mean that domestic operations face their own production bottlenecks and ramp-up delays.

When manufacturing capacity is tight and labor is constrained, operational flexibility becomes the primary defense against market surprises. You cannot afford to have finished devices trapped in inefficient loops.

True supply chain resilience requires looking past the factory floor.

If a manufacturer tightens controls on domestic production but leaves field inventory unmonitored, the waste simply migrates. Devices sitting unaccounted for in sales trunks, unrecorded hospital consignment, or delayed loaner trays erode margins just as quickly as overseas shipping delays.

The same chain of custody, visibility, and accountability expected inside a manufacturing plant must extend all the way to the point of care.

Tighter domestic production only succeeds when the field inventory system is accurate enough to back it up.

Read more about medtech reshoring in this article from Todd Shryock Medical Economics

https://t.co/rODuOyEecj

#medtech #medicaldevices #supplychain #operations #manufacturing

[ConnectSx @connectSX]

ASCs are evolving their operations to take on increasingly complex cases in orthopedics and cardiology, while also adapting to increasing supply chain pressures, necessarily shifting how they approach daily logistics.

According to a recent report from BECKER'S ASC REVIEW by Sophie Eydis, supply chain strategy is no longer treated as a background administrative chore; it has become a core requirement for protecting procedure-level margins.

ASCs are actively adopting sophisticated software, inventory tracking systems, and real-time case-costing tools to gain visibility into materials utilization and combat rising costs.

Medical device manufacturers must adapt alongside them. This change isn’t just about staying aligned with customers; manufacturers face their own escalating operational constraints, from SKU creep to field inventory waste. Developing operational maturity is now a necessity for success.

Inventory management is a financial strategy directly tied to margin protection, not just a logistical task:

When advanced surgical cases migrate to the outpatient setting, lower reimbursement rates and rising supply costs compress margins. ASCs are responding by utilizing data analytics to track exact spending per case.

For manufacturers, this means field inventory operations must be equally precise. If field inventory remains a blind spot, hidden margin erosion occurs long before finance notices the damage.

Disconnected systems lead to unreconciled trunk stock, mismatched billing, delays in post-case consumption data, and product expirations that could have been prevented with better allocation.

Managing complex outpatient cases requires tight coordination between sales representatives, distributors, and providers.

ASCs are managing real-time inventory risks, including ongoing device recalls and tariff-driven price fluctuations. To support these facilities effectively—and protect their own bottom lines—manufacturers must ensure that field data is reliable, accurate, and accessible.

When reps, distributors, and operations teams share visibility into field inventory, errors decrease, compliance improves, and billing cycles accelerate.

Manufacturers need to keep up with the operational demands of the market. Visibility in the field is no longer optional—it is a baseline operational requirement.

https://t.co/oxm8xqBry8

[ConnectSx @connectSX]

MedTech margins are facing a specific kind of pressure this year.

Global medical costs are projected to increase by 10.3% in 2026. Combined with rising international shipping fees, supply chain price increases of 2.41%, and the implementation of the new FDA Quality Management System Regulation (QMSR), the margin for operational error has effectively disappeared.

In this environment, the difference between a profitable quarter and a missed target often comes down to field execution. When inventory is scattered across trunk stock and hospital closets, it creates "invisible debt" through expirations and stockouts.

Tightening up execution in 2026 requires moving past manual spreadsheets. Success now depends on:

- Digitizing field activity: Moving data from the field into a cloud-based system of record in real-time.

- Operational reporting: Leveraging analytics-driven forecasting to maintain care continuity amid volatility.

- Workflow clarity: Establishing clean, integrated systems to detect and resolve inventory issues before they escalate.

Beacon helps you achieve this by digitizing your field activity and providing the operational reporting needed for informed business decisions.

Estimate your potential savings:

Use our ROI calculator to see how much fragmented execution is costing your team:

https://t.co/MQoSfRbwfk

[ConnectSx @connectSX]

Many medtech leaders are currently focused on tightening R&D discipline and planning portfolios on a ten-year horizon. But there is a gap between a disciplined R&D roadmap and the reality of how those products move through the field.

You can have a market-led development process and world-class lifecycle management, but if field inventory remains a black box, operational friction eats the ROI of that innovation.

When a high-value technology is launched into a fragmented system, the progress often stops at the warehouse door. From there, it enters a cycle of trunk stock confusion, emergency couriers, and manual reconciliation.

True lifecycle discipline doesn't end when a product is approved. It continues until that product is used, billed, and documented accurately.

If an innovation engine doesn't include the plumbing of field operations—specifically how teams see and move inventory in real-time—it isn't actually scaling innovation. It is just scaling complexity.

Operational clarity is a prerequisite for innovation, not an afterthought.

Read more about how medtech leaders are building their innovation engines in this insightful article from Vikram Aggarwal, Shruti Nayak, Beate Steen, Alok Sathaye, and Andrew Barbaccia of Boston Consulting Group (BCG): https://t.co/jCUcDwwuRM

[ConnectSx @connectSX]

You can’t drive "High-Velocity" sales with a "Low-Velocity" workflow. 🏎️

We're noticing a trend in strategy among medtech companies to consolidate and prioritize top-line sales velocity. For instance, Teleflex just appointed a new CEO, Jason Weidman, from Medtronic to lead their shift in focus towards core high-growth interventional markets. It’s a bold move toward a more focused, faster future.

But for many MedTech companies, "growth" is still hindered by "grind."

We see it all the time: Reps are expected to move at 100mph, but they are weighted down by:

- Fragmented marketing tools.

- Manual reporting and admin.

- Outdated silos between sales and operations.

At Beacon, we help organizations streamline these hurdles. We provide the "fluidity" that turns a strategic shift into measurable top-line revenue.

Is your sales stack ready for the speed of 2026? Let’s talk.

https://t.co/uJvQ87ZQlK

[ConnectSx @connectSX]

Pricing errors usually happen because sales reps are expected to be walking encyclopedias for every facility contract and catalog number in their territory. When you are trying to close out a case at the end of a long day, hunting through spreadsheets for a price list is a bottleneck that shouldn't exist.

Beacon has internalized contract pricing so the data is already there when you bill a case. The system matches the catalog number to the specific facility contract or health system tier automatically. It eliminates the back-and-forth with finance and ensures you aren't submitting bad data that holds up your commissions.

Whether you are uploading a list for one facility or applying a pricing structure across an entire health system, the goal is to make the administrative work move as fast as the surgery.

The video below shows how the platform handles this using global or reusable price lists. Check out our website, https://t.co/QGSqiiaJwE to schedule a live Demo or learn more!
https://t.co/3qQm9IkyU9

#medtech #medicaldevices #salesops #inventorymanagement

[ConnectSx @connectSX]

Many medtech companies treat a first-generation FDA clearance as the finish line, but as CEO Thomas Looby writes, for Conavi Medical it was the start of a deep refinement phase. After validating their hybrid imaging concept in 2018, they pivoted toward "operational maturity"—focusing on the specific barriers that prevent wide-scale adoption. By leveraging specialized manufacturing partners like Resolution Medical and Minnetronix Medical, they secured the expertise needed to produce complex consoles and catheters at scale. This allowed them to focus on ease of use and image quality while ensuring they could produce at scale with sustainable margins.

It’s a reminder that a successful commercial launch depends as much on the manufacturing partnerships and supply chain stability as it does on the clinical innovation itself.

https://t.co/8GkxMccy2M

[ConnectSx @connectSX]

The 75% failure rate for medtech startups isn't just a funding issue; it's a failure to bridge the gap between a working prototype and a scalable business. In this analysis, Scott Nelson of FastWave Medical highlights a critical thread in this article: successful med device companies survive by aggressively de-risking the "unsexy" parts of the business—manufacturing and clinical integration—long before they hit the mass market.

Technical innovation is only half the battle; the real hurdle is operational execution.

For manufacturers, this means moving away from the "outsourced-only" model that many startups rely on. CEOs like Conor Cullinane, PhD have found that bringing manufacturing in-house early is a way to tighten the feedback loop between the design and the reality of the production floor. It turns manufacturing into a competitive advantage rather than a bottleneck.

Building a device that works is the price of entry. Building an organization that can actually produce and distribute that device at scale is what keeps the lights on.

https://t.co/iTuRbnqD40

[ConnectSx @connectSX]

Establishing a presence in ASCs is a logical move for robotic surgery providers, but the operational reality of moving complex technology into smaller footprints is often overlooked.

While the surgical benefits are clear, the logistical shift creates a new set of pressures for manufacturers and distributors. ASCs don't have the same storage capacity, staffing levels, or processing infrastructure as large health systems.

The move toward ASCs raises critical questions for operations teams:

How do you manage the specialized instrument trays and high-value consumables required for robotics in a facility with limited storage?

Can your current field inventory system track product movement across dozens of smaller sites as accurately as it does for a central hospital?

As procedures move to the ASC, how do you prevent "inventory drift" where trays and implants become stranded in lower-volume accounts?

https://t.co/bO9faJw2p8

[ConnectSx @connectSX]

Scarcity is no longer a temporary hurdle in the medical device industry; it has become the new baseline for operations. As highlighted by this article from Antone Gonsalves and Supply Chain Dive, medical supply costs are projected to continue to rise in 2026.

While it's important to observe broad cost pressures, the real damage for orthopedic teams happens at the ground level where visibility is thin. High tariffs are forcing companies to absorb costs, while "inventory blindness" leads to over-production and hoarding to compensate for perceived shortages. This results in capital being tied up in stock that sits idle or expires in the field.

Adapting to this shift requires prioritizing data reliability over stockpiling. Moving away from manual reconciliation toward a system where every movement is captured immediately allows organizations to shift inventory to where demand is highest. By making field data precise and reliable, teams can identify cost leakage before it hits the quarterly report.

https://t.co/z8RmccU5rv

#medtech #supplychain #medicaldevices #operations #orthopedics

[ConnectSx @connectSX]

Medtech product performance data can be hard to track and aggregate when it is lost in transit, because it’s captured in the wrong places.

When a sales rep identifies a product issue or receives feedback during a case, that information can be communicated in a text message, an email, or a verbal conversation. For manufacturers, this creates a major visibility gap and burden of consolidating this information. You cannot improve product outcomes if the data required to track them is siloed or forgotten.

The problem isn't a lack of information—it's that the information isn't connected to the device.

Beacon’s tagging feature allows field teams to flag comments as Feedback or an Issue directly within the workflow. This does more than just aggregate notes; it maintains complete traceability by linking every report to the specific device and case in the system.

Eliminate Silos: Move field insights out of private messages and into one place for tracking and reporting.

Maintain Traceability: Keep feedback tied to the individual UDI and case history.

Improve Forecasting: Use real-world performance data to inform R&D and quality decisions.

Capturing data at the point of use turns anecdotal feedback into an operational asset.

See how to use feedback tags in Beacon: https://t.co/Abb9wft8Gm

#medtech #medicaldevices #operations #qualityassurance #supplychain

[ConnectSx @connectSX]

AdvaMed recently commended the RAPID pathway, a move designed to provide predictable and immediate Medicare coverage for breakthrough medical technologies.

As Scott Whitaker noted, the success of this pathway depends on "meaningful timelines" and "effective management".

The industry tends to view this "six-year gap" between FDA approval and reimbursement as a policy failure. But there is an operational reality we need to address: The gap is also a data latency problem.

To maintain "immediate" coverage, manufacturers must satisfy CMS’s ongoing demand for clinical evidence. You cannot meet "meaningful timelines" for evidence if your field data is on a 30-day+ lag.

This creates an operational bottleneck - CMS wants to see how a device performs in the real world, not just in a controlled trial.

If your usage data is trapped in paper logs or trunk stock, your ability to link specific devices to patient outcomes is delayed.

Manufacturers end up in a defensive posture, fighting to reconcile "dirty data" rather than proving clinical value.

We think of reimbursement as a regulatory hurdle, but it is also a visibility hurdle.

The RAPID pathway offers the "immediate" coverage the industry has been asking for. But the companies that will actually keep that coverage are those that can capture field data with the same precision they use in a clinical trial.

If you can’t see it, you can’t prove it.

https://t.co/NRoZytRvhE
hashtag#medtech hashtag#supplychain hashtag#medicare hashtag#operations hashtag#medicaldevices hashtag#AdvaMed

[ConnectSx @connectSX]

Food manufacturers are increasingly adopting RFID and digital twins to manage perishable inventory and volatile demand. While the industries differ, identical operational challenges can be found in medtech: managing high-value, regulated products with a limited shelf life.

In both sectors, the "invisible debt" of field inventory is the primary margin killer. When products live in satellite sites or hospital closets, visibility breaks. Using tools like barcode scanning or RFID isn't about the tech itself—it's about creating trust infrastructure so teams stop arguing over data, leverage real time information, and start fixing bottlenecks.

The takeaway for medtech ops is that system-level framing works across borders. If you can’t see the product, you can’t manage the expiration risk. Treat field data as an operational asset your team is going to rely on rather than a post-case guessing game or afterthought. Check out more about the tools the food industry are using to tackle common supply chain issues in Kelly Stroh's article from Supply Chain Dive:

https://t.co/OygSmvg50P
hashtag#medtech hashtag#supplychain hashtag#inventorymanagement hashtag#operationalexcellence hashtag#rfid

[ConnectSx @connectSX]

Operational inefficiencies in the medical device industry—like "invisible" trunk stock, unbilled usage, and manual data entry or handwritten records—often feel like a standard cost of doing business. However, these bottlenecks directly impact margins and distract sales teams from high-value clinical support.

To move from managing by guesswork to managing by data, you first need to quantify the cost of the status quo. We’ve developed a free ROI calculator specifically for medical device manufacturers and distributors to identify exactly where revenue is leaking.

By inputting your specific operational numbers, you can see the potential impact of automating field inventory and logistics. You might be looking at reducing inventory loss by up to 70% and saving 5–7 hours per person each week. Check out the calculator today to see what your operation could save:

https://t.co/QIrokTgp25

#medtech #medicaldevice #inventorymanagement #operationalexcellence #ROI

[ConnectSx @connectSX]

A year into new medtech tariffs, the focus has shifted from initial landed costs to the long-term strain on supply chain agility. While manufacturers try to diversify vendors, the real margin erosion happens in the field where fluctuations in lead-time turn "just-in-case" inventory into an expensive liability.

To navigate this successfully, try focusing on internal visibility. When external costs rise, you can no longer afford "invisible" costs like expired products, unbilled trunk stock, or manual reconciliation errors.

Resilience in 2026 isn't just about tax strategy; it's about eliminating the data blindness that eats margins. High-performing ops teams are making field data reliable so that every device moved is a device billed. Read more about how companies are faring in this article from Susan Kelly from Supply Chain Dive.

https://t.co/7Lv1xKtPih
hashtag#medtech hashtag#supplychain hashtag#medicaldevice hashtag#inventorymanagement hashtag#operations

[ConnectSx @connectSX]

Most reps aren’t slowed down by a lack of effort — they’re slowed down by the number of places they have to look just to understand what’s going on. Inventory in one system, case details in another, customer context somewhere else, and none of it comes together cleanly when it actually matters.

Now multiply that for every manufacturer a distributor represents...

There’s a reason teams are moving away from stacked tools toward something more connected. In a field environment where timing and accuracy can make or break a case, switching between systems isn’t just annoying — it creates gaps and possibility for error. When everything lives in one place and actually works in the moment, reps don’t have to piece together the story, they can act on it.

https://t.co/YN2cYljWJ5

#medtech #sales #fieldoperations #medicaldevices #salestech

[ConnectSx @connectSX]

Most field teams are communicating constantly — texts, calls, quick conversations after a case — but very little of that feedback actually makes it into a system where it can be tracked and acted on. A rep runs into a missing item, a tray issue, or a case delay, mentions it to someone, and then everyone moves on after it's resolved. By the time it comes up again, it’s harder to trace, harder to quantify, and easy to dismiss as a one-off.

Capturing “issue” and “feedback” tags at the moment something happens turns those conversations into something the business can actually use. Instead of relying on memory or digging through messages, teams get a clear record tied to real activity in the field. Over time, that creates visibility into patterns that would otherwise stay hidden, making it easier to fix recurring problems, tighten operations, and give leadership a more accurate view of what’s actually happening day to day.

https://t.co/q7yydWxwM2

#medtech #medicaldevices #fieldoperations #operationalexcellence

[ConnectSx @connectSX]

Hospital Value Analysis Committees (VACs) aren't rejecting new technology because the clinical data is lacking. They are often simply too overwhelmed to process the implementation. While 2025 brought significant technical and regulatory progress, the administrative systems at the facility level haven't kept pace.

For sales reps, this means a "yes" from a surgeon is only the beginning of a much longer operational battle. The real hurdle in 2026 is moving a product through a system that lacks the bandwidth to onboard it. Success now depends less on the pitch and more on helping the hospital manage the logistical weight of the change.

Check out what leaders like Thomas Hickey and Andrew Berkeley are saying about these operational constraints in this article from Citeline: https://t.co/3nY3oZhhwn

#medtech #valueanalysis #medicaldevices #hospitaloperations

[ConnectSx @connectSX]

The gap between when an issue begins and when action is taken is often wider than most teams expect, but this delay can mean silence. And silence in a recall scenario can cost you and your customers.

This MD+DI piece from Amanda Pedersen highlights the impacts when signals aren't surfaced urgently, investigations delay in moving forward, and decisions like recalls or inventory holds are not urgently executed. Her article addresses intentional delay specifically, but the same result can result from antiquated, manual, or bloated operations. By the time those actions happen, the impact has already spread across inventory, provider relationships, and internal operations.

That delay usually traces back to visibility and coordination. When quality data, field activity, and inventory records aren’t tightly connected, even well-understood issues take longer to trace and contain. For manufacturers, distributors, and reps, that shows up as uncertainty in the field — what’s affected, what can still be used, and what needs to be pulled — and the longer that window stays open, the more operational friction builds.

https://t.co/0syQaa4W8Z

#medtech #medicaldevices #quality #regulatory #operations